Razoxanum [Inn-Latin] en es it fr

Category

Razoxanum_[Inn-Latin]
add to favotites goo dig stu tec squ mys
fac del pro twi yah mya far


Razoxanum [Inn-Latin] Brand names, Razoxanum [Inn-Latin] Analogs

Razoxanum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Razoxanum [Inn-Latin] Chemical_Formula

C11H16N4O4

Razoxanum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic2/dexrazoxane.htm

Razoxanum [Inn-Latin] fda sheet

Razoxanum_[Inn-Latin] FDA

Razoxanum [Inn-Latin] msds (material safety sheet)

Razoxanum_[Inn-Latin] MSDS

Razoxanum [Inn-Latin] Synthesis Reference

No information avaliable

Razoxanum [Inn-Latin] Molecular Weight

268.269 g/mol

Razoxanum [Inn-Latin] Melting Point

191 - 197 oC

Razoxanum [Inn-Latin] H2O Solubility

Sparingly soluble

Razoxanum [Inn-Latin] State

Solid

Razoxanum [Inn-Latin] LogP

-2.135

Razoxanum [Inn-Latin] Dosage Forms

Liquid; Powder for solution

Razoxanum [Inn-Latin] Indication

For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.

Razoxanum [Inn-Latin] Pharmacology

Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose.

Razoxanum [Inn-Latin] Absorption

IV administration results in complete bioavailability.

Razoxanum [Inn-Latin] side effects and Toxicity

Intraperitoneal, mouse LD10 = 500 mg/kg. Intravenous, dog LD10 = 2 gm/kg.

Razoxanum [Inn-Latin] Patient Information

No information avaliable

Razoxanum [Inn-Latin] Organisms Affected

Humans and other mammals